FowkesFGRRudanDRudanI, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329–1340.
3.
MustaphaJADiaz-SandovalLJ. Plaque composition in the proximal SFA and clinical outcomes in patients with claudication. Have we found the answer?JACC Cardiovasc Imaging. 2017;10:1013–1015.
4.
GrayBHDiaz-SandovalLJDieterRS, et al. SCAI Expert consensus statement for infrapopliteal arterial intervention appropriate use. Catheter Cardiovasc Interv. 2104;84:539–545.
5.
GarciaLJaffMRMetzgerC, et al. Wire-interwoven nitinol stent outcome in the superficial femoral and proximal popliteal arteries. twelve-month results of the SUPERB trial. Circ Cardiovasc Interv. 2015;8:e000937. doi:10.1161/CIRCINTERVENTIONS.113.000937.
6.
DudaSHBosiersMLammerJ, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701–710.
7.
Ní GhriallaisRHeratyKSmouseB, et al. Deformation of the femoropopliteal segment: effect of stent length, location, flexibility, and curvature. J Endovasc Ther. 2016;23:907–918.
8.
LairdJR. Limitations of percutaneous transluminal angioplasty and stenting for the treatment of disease of the superficial femoral and popliteal arteries. J Endovasc Ther. 2006;13(suppl 2):II30–II40.
9.
KatsanosKSpiliopoulosSParaskevopoulosI, et al. Systematic review and meta-analysis of randomized controlled trials of paclitaxel-coated balloon angioplasty in the femoropopliteal arteries: role of paclitaxel dose and bioavailability. J Endovasc Ther. 2016;23:356–370.
10.
KatsanosKSpiliopoulosSKarunanithyN, et al. Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery. J Vasc Surg. 2014;59:1123–1133.e8.
11.
KatsanosKSpiliopoulosSKitrouP, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245. doi:10.1161/JAHA.118.011245.
12.
ArmstrongEJJeon-SlaughterHKahlonRS, et al. Comparative outcomes of Supera interwoven nitinol vs bare nitinol stents for the treatment of femoropopliteal disease: insights from the XL-PAD tegistry. J Endovasc Ther. 2020;27(1):58–63.
13.
GarciaLARosenfieldKRMetzgerCD, et al; SUPERB investigators. SUPERB final 3-year outcomes using interwoven nitinol biomimetic supera stent. Catheter Cardiovasc Interv. 2017;89:1259–1267.
14.
TepeGLairdJSchneiderP, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495–502.
15.
LairdJRSchneiderPATepeG, et al. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66:2329–2338.
16.
RosenfieldKJaffMRWhiteCJ, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–153.
17.
TeymenBAkturkSAkturkU, et al. Comparison of drug-eluting balloon angioplasty with self-expanding interwoven nitinol stent deployment in patients with complex femoropopliteal lesions. Vascular. 2018;26:54–61.
18.
PalenaLMDiaz-SandovalLJSultatoE, et al. Feasibility and 1-year outcomes of subintimal revascularization with supera stenting of long femoropopliteal occlusions in critical limb ischemia: The “Supersub” Study. Catheter Cardiovasc Interv. 2017;89:910–920.
